Middle East & Africa Acute Pancreatitis Market Forecast to 2030 - Regional Analysis

Description

List of Tables

The Middle East & Africa acute pancreatitis market was valued at US$ 131.64 million in 2022 and is expected to reach US$ 156.24 million by 2030; it is estimated to grow at a CAGR of 2.2% from 2022 to 2030.

Advancements in Specific Acute Pancreatitis Treatments Fuels the Middle East & Africa Acute Pancreatitis Market

Acute pancreatitis is an inflammatory disorder of the pancreas. The condition is associated with increased morbidity and mortality because there is no specific treatment approved to treat it, leaving supportive care as the main course of treatment. A targeted novel treatment strategy that halts disease progression and improves patient outcomes is needed to address the current disease burden of acute and severe acute pancreatitis. An article published in the National Library of Medicine in February 2023 focuses on 3 major approaches to advance acute pancreatitis treatments-the clinical identification and application of new genetic information; newly identified serum biomarkers, i.e., fatty acid ethyl esters (FAEEs); and acceleration in timing of early nutrition feedings in acute pancreatitis.

Clinical Identification and Application of New Genetic Information: When acute pancreatitis occurs at the age of 35 years or when it is relapsing or idiopathic, testing for the 6 commercially evaluable genetic causes of acute pancreatitis is recommended. This test provides valuable information regarding the diagnosis probability of genetic predisposition, cofactors that are likely to play a role in disease identification and a suitable approach to initiate treatment early in the process, without requiring repeated testing. Newly Identified Serum Biomarkers-FAEEs: During a prospective, blinded trial, researchers compared the levels of FAEE, nonesterified fatty acids, and ethanol in the blood of 175 patients hospitalized for alcoholic pancreatitis, alcohol intoxication, nonalcoholic pancreatitis, and normal controls. This test has the unique capability of demonstrating diagnostic elevations of FAEEs associated with alcohol consumption. Therefore, it can be evaluated that alcohol is the cause of alcohol-associated pancreatitis and to exclude it when there are other causes. Important Acceleration in Timing of Early Feedings in Acute Pancreatitis: The practice of beginning early feeding through the nasogastric/nasojejunal routes after the onset of acute pancreatitis has been supported by multiple randomized controlled trials and has replaced the practice of resting the gastrointestinal tract until pain subsides prior to feeding. This approach results in increased bowel motility and reduced organ failure, infection, length of stay, and mortality rates, confirming that an idle intestine leads to bacterial overgrowth, increased permeability, and bacterial translocation.

Such developments in specific treatment approaches would lead to new treatment options to enhance outcomes and improve the acute pancreatitis market in the near future.

Middle East & Africa Acute Pancreatitis Market Overview

The Middle East & Africa acute pancreatitis market is segmented into UAE, Saudi Arabia, South Africa, and the Rest of the Middle East & Africa. The growing geriatric population, growing healthcare infrastructure, and adoption of advanced technologies in healthcare are the factors that support the growth of the market in the region.

Saudi Arabia is one of the fastest-growing countries in the Middle East & Africa. Changing healthcare infrastructure and public-private partnerships between government and international players are strengthening the healthcare sector in the country. These partnerships and privatization efforts are in line with the policies included in the "Vision 2030" strategy by the Saudi government for the transformation national economy. As per the "Rights and Wellbeing of Older Persons in Saudi Arabia" report, the number of people aged 60 or more is predicted to increase five-fold during 2020-2050, rising from 2 million (5.9% of the total population) to 10.5 million (23.7% of the population). Also, the number of people aged 80 or more is expected to reach 1.6 million, i.e., 4% of the total population by 2050. As per a study titled "Epidemiological Features of Acute Pancreatitis," published in 2023, gallstones and alcohol consumption are the leading causes of acute pancreatitis, together accounting for 60% of the total cases in Saudi Arabia. Acute pancreatitis incidence among patients suffering from abdominal pain was 11.6% during 2017-2021. Concerning the incidence rate of the condition between genders, many Saudi researchers over the last 3 decades have agreed that acute pancreatitis is more prevalent in males than in females.

Middle East & Africa Acute Pancreatitis Market Revenue and Forecast to 2030 (US$ Mn)

Middle East & Africa Acute Pancreatitis Market Segmentation

The Middle East & Africa acute pancreatitis market is segmented offerings, causes, end user, and country.

Based on offerings, the Middle East & Africa acute pancreatitis market is segmented into medications, diagnosis, and others. The diagnosis segment held the largest market share in 2022.

Based on causes, the Middle East & Africa acute pancreatitis market is segmented into gallstones, alcoholism, genetic disorders, infection, and others. The gallstones segment held the largest market share in 2022.

Based on end user, the Middle East & Africa acute pancreatitis market is divided into hospitals, diagnostic laboratories, ambulatory surgical centres, and others. The hospitals segment held the largest market share in 2022.

Based on country, the Middle East & Africa acute pancreatitis market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa acute pancreatitis market in 2022.

Abbott Laboratories, Baxter International Inc, Boston Scientific Corp, Fresenius Kabi AG, GE HealthCare Technologies Inc, Koninklijke Philips NV, Medtronic Plc, and Samsung Healthcare are some of the leading companies operating in the Middle East & Africa acute pancreatitis market.

Product Code: BMIRE00029231

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights
2.2 Middle East & Africa Acute Pancreatitis Market, by Country (US$ Million)

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Middle East & Africa Acute Pancreatitis Market Landscape

4.1 Overview

5. Middle East & Africa Acute Pancreatitis Market - Key Industry Dynamics

5.1 Key Market Drivers
- 5.1.1 Rise in Pancreatic Cancer Cases Due to Acute Pancreatitis
- 5.1.2 Rising Incidence of Diabetes Following Acute Pancreatitis
5.2 Key Market Restraints
- 5.2.1 Side Effects of Pancreatitis and Pancreatic Cancer Treatments
5.3 Key Market Opportunities
- 5.3.1 Upsurge in Number of R&D Activities and Awareness Programs on Acute Pancreatitis
5.4 Future Trends
- 5.4.1 Advancements in Specific Acute Pancreatitis Treatments
5.5 Impact Analysis:

6. Acute Pancreatitis Market - Middle East & Africa Market Analysis

6.1 Middle East & Africa Acute Pancreatitis Market Revenue (US$ Mn), 2022 - 2030

7. Middle East & Africa Acute Pancreatitis Market - Revenue and Forecast to 2030 - by Offerings

7.1 Overview
7.2 Middle East & Africa Acute Pancreatitis Market Revenue Share, by Offerings, 2022 & 2030 (%)
7.3 Medications
- 7.3.1 Overview
- 7.3.2 Medications: Middle East & Africa Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
  - 7.3.2.1 Middle East & Africa Acute Pancreatitis Market, by Medications, 2020-2030 (US$ Million)
7.4 Diagnosis
- 7.4.1 Overview
- 7.4.2 Diagnosis: Middle East & Africa Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
  - 7.4.2.1 Middle East & Africa Acute Pancreatitis Market, by Diagnosis, 2020-2030 (US$ Million)
7.5 Others
- 7.5.1 Overview
- 7.5.2 Others: Middle East & Africa Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)

8. Middle East & Africa Acute Pancreatitis Market - Revenue and Forecast to 2030 - by Causes

8.1 Overview
8.2 Middle East & Africa Acute Pancreatitis Market Revenue Share, by Causes 2022 & 2030 (%)
8.3 Gallstones
- 8.3.1 Overview
- 8.3.2 Gallstones: Middle East & Africa Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Alcoholism
- 8.4.1 Overview
- 8.4.2 Alcoholism: Middle East & Africa Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Genetic Disorders
- 8.5.1 Overview
- 8.5.2 Genetic Disorders: Middle East & Africa Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
8.6 Infections
- 8.6.1 Overview
- 8.6.2 Infections: Middle East & Africa Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
8.7 Others
- 8.7.1 Overview
- 8.7.2 Others: Middle East & Africa Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)

9. Middle East & Africa Acute Pancreatitis Market - Revenue and Forecast to 2030 - by End User

9.1 Overview
9.2 Middle East & Africa Acute Pancreatitis Market Revenue Share, by End User, 2022 & 2030 (%)
9.3 Hospitals
- 9.3.1 Overview
- 9.3.2 Hospitals: Middle East & Africa Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Diagnostic Laboratories
- 9.4.1 Overview
- 9.4.2 Diagnostic Laboratories: Middle East & Africa Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
9.5 Ambulatory Surgical Centers
- 9.5.1 Overview
- 9.5.2 Ambulatory Surgical Centres: Middle East & Africa Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)
9.6 Others
- 9.6.1 Overview
- 9.6.2 Others: Middle East & Africa Acute Pancreatitis Market - Revenue and Forecast to 2030 (US$ Million)

10. Middle East & Africa Acute Pancreatitis Market - Country Analysis

10.1 Overview

11. Middle East & Africa Acute Pancreatitis Market-Industry Landscape

11.1 Overview
11.2 Growth Strategies in the Middle East & Africa Acute Pancreatitis Market
11.3 Inorganic Growth Strategies
- 11.3.1 Overview
11.4 Organic Growth Strategies
- 11.4.1 Overview

12. Company Profiles

12.1 Abbott Laboratories
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 GE HealthCare Technologies Inc
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Samsung Healthcare
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Koninklijke Philips NV
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Baxter International Inc
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Medtronic Plc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Boston Scientific Corp
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
12.8 Fresenius Kabi AG
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments

13. Appendix

13.1 About Us
13.2 Glossary of Terms